Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells

Motohiko Tanino, Ryo Matoba, Seiji Nakamura, Hideto Kameda, Kouichi Amano, Toshitsugu Okayama, Hayato Nagasawa, Katsuya Suzuki, Kenichi Matsubara, Tsutomu Takeuchi

Research output: Contribution to journalArticle

37 Citations (Scopus)


Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients has revolutionized the treatment of this disease. However, biomarkers for predicting the efficacy of the drug at an early phase of treatment for selecting real responders have not been found. We here present predictive markers based on a thorough transcriptome analysis of white blood cells from RA patients. RNA from whole blood cells of consecutive 42 patients before the first infusion was analyzed with microarrays for training studies. Samples from the subsequent 26 consecutive patients were used for a prospective study. We categorized the results into no inflammation and residual inflammation groups using the serum C-reactive protein (CRP) level at 14 weeks after the first infusion. The accuracy of prediction in our study was 65.4%.

Original languageEnglish
Pages (from-to)261-265
Number of pages5
JournalBiochemical and Biophysical Research Communications
Issue number2
Publication statusPublished - 2009 Sep 18
Externally publishedYes



  • Anti-TNF-α antibody
  • Biomarker
  • C-reactive protein
  • DNA microarray
  • Gene expression
  • Infliximab
  • Methotrexate
  • Peripheral blood RNA
  • Rheumatoid arthritis
  • Transcriptome

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this